Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Using AI to Improve Sepsis Quality of Care in the Emergency Department

5 mei 2026 bijgewerkt door: Gabriel Wardi, University of California, San Diego

Impact of Automated Sepsis Metric Evaluation on Provider Performance

Sepsis is a life-threatening condition caused by the body's response to infection and is a leading cause of death worldwide. Hospitals use a complex quality measure called SEP-1 to track whether patients with severe sepsis or septic shock receive recommended care, such as timely antibiotics, fluids, and laboratory testing. However, evaluating SEP-1 is difficult. It requires manual review of medical records, is time-consuming and expensive, and typically provides feedback to clinicians months after care is delivered. This delay limits the ability to improve care in real time.

This study tested whether artificial intelligence (AI), specifically a type of system called a large language model (LLM), could improve the quality of sepsis care by providing faster and more detailed feedback to physicians.

The study was conducted at two emergency departments within a large academic health system. Sixty-six attending physicians were randomly assigned to one of two groups. In the intervention group, the AI system reviewed each patient's medical record at the time of hospital discharge and determined whether SEP-1 care standards were met. Physicians then received near real-time, individualized feedback about their performance, including specific areas for improvement. In the control group, physicians received standard feedback based on a small sample of cases reviewed months later using traditional methods.

Studie Overzicht

Toestand

Voltooid

Conditie

Gedetailleerde beschrijving

Sepsis is a leading cause of morbidity and mortality worldwide and remains a major focus of hospital quality improvement efforts. In the United States, the Centers for Medicare & Medicaid Services (CMS) Severe Sepsis and Septic Shock Management Bundle (SEP-1) is a publicly reported quality measure that evaluates adherence to evidence-based processes of care, including timely antibiotic administration, fluid resuscitation, and laboratory testing. Despite its importance, SEP-1 is widely recognized as a complex measure, consisting of dozens of individual elements that must be completed within specific timeframes. Assessment of compliance typically relies on manual chart abstraction, which is resource-intensive, subject to variability, and performed on a small subset of cases with delays of several months. These limitations reduce the ability of SEP-1 reporting to drive timely improvements in clinical care.

Advances in artificial intelligence (AI), particularly large language models (LLMs), offer an opportunity to automate the extraction and interpretation of clinical information from unstructured medical records. Prior work has demonstrated that LLMs can achieve high agreement with expert reviewers when applied to complex clinical abstraction tasks. Building on this foundation, this study evaluates whether integrating AI-enabled chart abstraction into a real-world clinical workflow can improve performance on a complex quality measure by providing near real-time feedback to clinicians.

This study was conducted as a prospective, cluster randomized quality improvement initiative across two academic emergency departments within a single health system. Attending emergency physicians were randomized at the provider level to either an intervention group receiving AI-generated feedback or a control group receiving standard quality reporting feedback. Randomization at the physician level was selected to minimize contamination while preserving real-world clinical workflows.

All adult patients presenting to the emergency department who met CMS criteria for severe sepsis or septic shock were eligible for inclusion. Cases were identified using clinical encounter diagnoses and evaluated according to SEP-1 specifications. Each case was classified as meeting or failing the measure based on completion of required elements within defined time windows.

In the intervention arm, an LLM-based system automatically reviewed each eligible patient encounter at the time of emergency department discharge. The system analyzed structured and unstructured clinical data to determine SEP-1 compliance and identify specific elements of care that were incomplete or not documented. Physicians received individualized feedback shortly after patient care was completed. Feedback included a summary of the case, the determination of compliance, and targeted recommendations for improvement when deficiencies were identified. In selected cases, additional follow-up communication was provided to reinforce learning and clarify opportunities for improvement.

In the control arm, physicians received feedback through standard institutional processes. This consisted of manual chart abstraction of a limited number of cases selected for CMS reporting, with results communicated weeks to months after the clinical encounter. This approach reflects the current standard of care in most health systems.

The primary objective of the study was to evaluate whether near real-time, AI-enabled feedback improves SEP-1 compliance compared to standard delayed feedback. Secondary objectives included assessing the agreement between AI-generated determinations and expert human reviewers, as well as evaluating selected patient-centered outcomes, including intensive care unit (ICU) admission and 30-day mortality.

Because randomization occurred at the physician level and outcomes were measured at the patient encounter level, analyses accounted for clustering of patients within physicians. Mixed-effects modeling was used to estimate the effect of the intervention while accounting for this hierarchical structure.

The intervention is grounded in established principles of audit-and-feedback, a widely used strategy for improving clinician performance. Prior research suggests that audit-and-feedback interventions are more effective when feedback is timely, individualized, and actionable. The AI-enabled system in this study was designed to address known limitations of traditional feedback approaches by evaluating all eligible cases rather than a small sample, reducing delays between care delivery and feedback, and providing specific guidance tailored to individual clinician performance.

Importantly, this study focuses on improving adherence to a process-based quality measure rather than directly modifying clinical decision-making at the point of care. As such, the intervention is intended to support clinician learning and quality improvement without introducing real-time clinical decision support alerts that may contribute to alert fatigue.

This study also evaluates the feasibility of integrating AI tools into routine clinical operations at scale. By automating chart review and feedback generation, the intervention has the potential to reduce the administrative burden associated with quality reporting and to enable continuous performance monitoring across all eligible patients.

While improved compliance with SEP-1 may have implications for hospital quality metrics and reimbursement, the relationship between SEP-1 adherence and patient-centered outcomes remains an area of ongoing investigation. This study is not powered to detect differences in mortality or other clinical outcomes, but it provides an important step in understanding how AI can be leveraged to improve quality measurement and feedback processes.

The findings of this study may have broader implications beyond sepsis care. The ability of AI systems to extract clinical context from electronic health records and deliver timely, targeted feedback could be applied to a wide range of quality and safety measures. This approach may support the development of learning health systems in which data generated during routine care are continuously used to inform and improve clinical practice.

In summary, this study evaluates a novel application of AI to enhance quality measurement and feedback in sepsis care. By addressing key limitations of existing reporting systems, this approach aims to improve clinician performance on a complex quality measure and to establish a scalable model for AI-enabled quality improvement in healthcare.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

66

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • California
      • San Diego, California, Verenigde Staten, 92103-1911
        • UC San Diego Health

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • Adult patients (≥18 years) evaluated in the emergency department Clinical diagnosis of severe sepsis or septic shock during the emergency department encounter Cases meeting Centers for Medicare & Medicaid Services (CMS) SEP-1 inclusion criteria Patient encounter managed by an attending emergency physician participating in the study Sepsis "time zero" occurring during the emergency department visit

Exclusion Criteria:

  • Patients who do not meet CMS SEP-1 criteria for severe sepsis or septic shock Sepsis onset occurring prior to emergency department arrival or after hospital admission Encounters without sufficient clinical documentation to assess SEP-1 compliance Patients transferred from another facility with ongoing sepsis care already initiated Cases in which the attending physician of record is not assigned to a study arm

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ander
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Intervention group
Participants in the intervention arm receive near-real-time, individualized feedback on SEP-1 performance generated by a large language model (LLM) that performs automated chart abstraction at the time of emergency department discharge.
Participants in the intervention arm receive near-real-time, individualized feedback on SEP-1 performance generated by a large language model (LLM) that performs automated chart abstraction at the time of emergency department discharge.
Geen tussenkomst: Control group
Participants in the control arm receive standard sepsis quality feedback processes without real-time augmentation. This is much less than the intervention group and typically 3-4 months after a particular interaction.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
SEP-1 Compliance
Tijdsspanne: This was assessed from time of the event (e.g., development of severe sepsis / septic shock) up to 1 month after the event.
SEP-1 (the Severe Sepsis and Septic Shock Early Management Bundle) is a quality measure developed by the Centers for Medicare & Medicaid Services that evaluates whether patients with sepsis receive a set of time-sensitive interventions and diagnostic tests. It is a binary process measure (e.g., either a "pass" or "fail").
This was assessed from time of the event (e.g., development of severe sepsis / septic shock) up to 1 month after the event.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
In-hospital mortality
Tijdsspanne: From when the patient arrives to the hospital to their discharge, either alive or expired, up to 6 months after the event (development of severe sepsis / septic shock).
Whether a patient survives or dies during a hospitalization.
From when the patient arrives to the hospital to their discharge, either alive or expired, up to 6 months after the event (development of severe sepsis / septic shock).

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 december 2024

Primaire voltooiing (Werkelijk)

1 augustus 2025

Studie voltooiing (Werkelijk)

12 december 2025

Studieregistratiedata

Eerst ingediend

13 april 2026

Eerst ingediend dat voldeed aan de QC-criteria

5 mei 2026

Eerst geplaatst (Werkelijk)

12 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 mei 2026

Laatste update ingediend die voldeed aan QC-criteria

5 mei 2026

Laatst geverifieerd

1 oktober 2024

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

This is a quality improvement investigation completed at UCSD. Although registered, a key component of our quality approval is that the data be only for UCSD patients and healthcare workers. Thus, we have elected not to share information of patients or healthcare workers.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Klinische onderzoeken op Sepsis

Abonneren